DK1168923T3 - DNA vaccination til behandling af autoimmune sygdomme - Google Patents

DNA vaccination til behandling af autoimmune sygdomme

Info

Publication number
DK1168923T3
DK1168923T3 DK00912207T DK00912207T DK1168923T3 DK 1168923 T3 DK1168923 T3 DK 1168923T3 DK 00912207 T DK00912207 T DK 00912207T DK 00912207 T DK00912207 T DK 00912207T DK 1168923 T3 DK1168923 T3 DK 1168923T3
Authority
DK
Denmark
Prior art keywords
treatment
autoimmune diseases
dna vaccination
vaccination
recipient
Prior art date
Application number
DK00912207T
Other languages
English (en)
Inventor
Lawrence Stanford Uni Steinman
Pedro Jose Stanford Uni S Ruiz
Hideki Dept Of Neurolog Garren
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK1168923T3 publication Critical patent/DK1168923T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00912207T 1999-03-12 2000-03-10 DNA vaccination til behandling af autoimmune sygdomme DK1168923T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26759099A 1999-03-12 1999-03-12

Publications (1)

Publication Number Publication Date
DK1168923T3 true DK1168923T3 (da) 2006-03-20

Family

ID=23019424

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00912207T DK1168923T3 (da) 1999-03-12 2000-03-10 DNA vaccination til behandling af autoimmune sygdomme
DK05015105.9T DK1621208T3 (da) 1999-03-12 2000-03-10 DNA-vaccination til behandling af sutoimmun sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05015105.9T DK1621208T3 (da) 1999-03-12 2000-03-10 DNA-vaccination til behandling af sutoimmun sygdom

Country Status (9)

Country Link
EP (3) EP1621208B1 (da)
JP (1) JP2003508346A (da)
AT (2) ATE453404T1 (da)
CA (1) CA2363269C (da)
DE (2) DE60023673T2 (da)
DK (2) DK1168923T3 (da)
ES (2) ES2338890T3 (da)
PT (1) PT1621208E (da)
WO (1) WO2000053019A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322185A3 (en) * 2001-11-21 2011-08-10 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
WO2008066330A1 (en) 2006-11-30 2008-06-05 Medipost Co., Ltd. Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
CN100571786C (zh) * 2007-03-26 2009-12-23 中国农业大学 一种预防和/或治疗自身免疫疾病的疫苗
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
EP2670421B1 (en) 2011-02-02 2017-12-06 Medipost Co., Ltd. Use of icam-1 for prevention or treatment of neurological diseases
GB201112806D0 (en) * 2011-07-26 2011-09-07 Bauer Johann Use of epitopes inducing specific tolerance for the prevention of tissue rejection
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
KR20170034701A (ko) * 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
US10898590B2 (en) 2015-09-21 2021-01-26 Kolon Life Science, Inc. Method for delivery of biological molecule to nervous tissue
WO2023086969A2 (en) * 2021-11-12 2023-05-19 Ichor Medical Systems Inc. Treatment methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891435A (en) 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
AU3225097A (en) * 1996-06-03 1998-01-05 Auragen, Inc. Immunotherapy for autoimmune disease

Also Published As

Publication number Publication date
EP1168923B1 (en) 2005-11-02
CA2363269A1 (en) 2000-09-14
WO2000053019A1 (en) 2000-09-14
ATE453404T1 (de) 2010-01-15
DE60023673T2 (de) 2006-07-20
ATE308244T1 (de) 2005-11-15
EP1621208B1 (en) 2009-12-30
ES2338890T3 (es) 2010-05-13
DE60043624D1 (de) 2010-02-11
EP1168923A1 (en) 2002-01-09
DE60023673D1 (de) 2005-12-08
DK1621208T3 (da) 2010-05-10
EP1168923A4 (en) 2002-06-26
PT1621208E (pt) 2010-04-07
EP2177228A1 (en) 2010-04-21
ES2251974T3 (es) 2006-05-16
CA2363269C (en) 2012-06-12
JP2003508346A (ja) 2003-03-04
EP1621208A1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
DK1168923T3 (da) DNA vaccination til behandling af autoimmune sygdomme
DE69737969D1 (de) Dns-impfung zur einleitung einer suppressiven t-zell-antwort
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
MXPA04000982A (es) Metodos para movilizar celulas progenitoras/madre.
HK1078777A1 (en) Modified vaccinia virus ankara for the vaccination of neonates
FI932678A (fi) Pao alfavirus baserande dna expressionssystem
ATE405243T1 (de) Säuglingspflegevorrichtung
DK2921500T3 (da) Genetisk modificerede, humane, naturlige dræbercellelinjer
AR026059A1 (es) Virus de plantas modificadas y metodos para su uso
DK0473252T3 (da) Anvendelse af L-deprenyl til forsinkelse af alderdomssvækkelse
DK0879056T3 (da) Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
Adachi et al. Expressions of peroxisome proliferator‐activated receptors (PPAR s) are directly influenced by permeability barrier abrogation and inflammatory cytokines and depressed PPAR α modulates expressions of chemokines and epidermal differentiation‐related molecules in keratinocytes
PT1699480E (pt) AGENTE TERAPjUTICO ANTI-TUMORAL ALOGÉNICO
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
ES2147747T3 (es) Celulas atrapadas y su utilizacion como medicamento.
SG165996A1 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
DE60033397D1 (de) Methode zur steigerung der produktionsleistung in tieren
PT858345E (pt) Uso de muteinas de citocinas do tipo selvagem como imunogenios
DK1100515T3 (da) Ex vivo-behandling af allogene og xenogene T-celler med pg39-antagonister
EP4414033A3 (en) Treatment involving car-engineered t cells and cytokines
DK0401997T3 (da) Fremgangsmåde til fremtilling af metastaseringsinhiberende faktor
David Review of Psychologische Grundlagenforschung: Ethik und Recht.